1534TiP Valproic acid combinEd with Simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic Pancreatic Adenocarcinoma patients-VESPA trial.

MLA

Budillon, A., et al. “1534TiP Valproic Acid CombinEd with Simvastatin and Gemcitabine/Nab-Paclitaxel-Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients-VESPA Trial.” Annals of Oncology, vol. 35, Sept. 2024, p. S935. EBSCOhost, https://doi.org/10.1016/j.annonc.2024.08.2129.

APA

Budillon, A., Silvestro, L., Reni, M., Milella, M., Tortora, G., Rodriguez, M., Fiore, F., Petrillo, A., De Bellis, M., Cavalcanti, E., Macchini, M., Leone, A., Di Gennaro, E., Passaro, E., Borrelli, M., García Bermejo, M. L., Hewitt, E., Fuchs, C., Giannarelli, D., & Avallone, A. (2024). 1534TiP Valproic acid combinEd with Simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic Pancreatic Adenocarcinoma patients-VESPA trial. Annals of Oncology, 35, S935. https://doi.org/10.1016/j.annonc.2024.08.2129

Chicago

Budillon, A., L. Silvestro, M. Reni, M. Milella, G. Tortora, M. Rodriguez, F. Fiore, et al. 2024. “1534TiP Valproic Acid CombinEd with Simvastatin and Gemcitabine/Nab-Paclitaxel-Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients-VESPA Trial.” Annals of Oncology 35 (September): S935. doi:10.1016/j.annonc.2024.08.2129.